88 优惠券
2020年3月1日到期。满 200 元可用
立即使用
立即使用
  • 参会报名
  • 会议通知
  • 会议日程
  • 会议嘉宾
  • 参会指南
  • 手机下单 手机扫码下单

首页 > 商务会议 > 医疗医学会议 > Biofuture 2022 第三届生物医药未来领袖峰会 更新时间:2021-07-06T10:14:07

Biofuture 2022 第三届生物医药未来领袖峰会
收藏3人
分享到

Biofuture 2022 第三届生物医药未来领袖峰会

会议时间: 2022-01-11 09:00至 2022-01-12 18:00结束

会议地点: 上海  详细地址会前通知   周边酒店预订

会议规模:1200人

主办单位: 封仕生物

门票名称单价截止时间数量
普通票 早鸟票(2021年9月1日前):1500/人(包含午餐和会议资料) 普通票:2500/人(包含午餐和会议资料) ¥2500.0 2022-01-07 17:00

会议通知

会议内容 主办方介绍


Biofuture 2022 第三届生物医药未来领袖峰会

Biofuture 2022 第三届生物医药未来领袖峰会宣传图

五大主题论坛齐聚:第三届创新抗体药物发现论坛,第三届细胞与基因治疗创新论坛,第二届CDMO未来发展论坛,临床前与临床开发论坛,小分子与创新药论坛

 

会议规模:1200人+

时间:2022年1月11-12日

地点:上海

合作协会:上海市生物医药行业协会

 

第三届创新抗体药物发现论坛主要话题:

 

ADCs全球与国内趋势纵览/Overview of ADCs Global and Domestic Trends

ADC药物定点偶联技术及成药性的研究趋势纵览/ Overview of the research

ADC药物研发面临的挑战和机遇/Challenges and opportunities facing ADC干细胞药物的发现研究

下一代ADC药物研发/Next-generation ADC drug development

抗体偶联药物(ADC)的临床方案设计与检测/ Design and testing of the clinical program of antibody-conjugated drugs (ADC)

ADC药物蓬勃发展: CDMO发展机遇和挑战/ ADC drugs are booming: CDMO development opportunities and challenges

迎接挑战与机遇,抗体药物研发战略布局/Facing challenges and opportunities, the strategic layout of antibody drug R&D

CD28是否会打破双特异抗体的格局/Will CD28 break the pattern of bispecific antibodies?

双特异性抗体创新药研发: 新靶点和组合/Bispecific antibody innovation drug development: new targets and combinations

新一代免疫检查点药物开发/Development of a new generation of immune checkpoint drugs

圆桌讨论: 百花齐放的双抗/The booming of Bispecific antibody drug development

重组蛋白类药物的研发现状与趋势/Current status and trend of research and development of recombinant protein drugs

靶向CD47/SIRPα药物研发进展和未来展望/Development and future prospects of drugs targeting CD47/SIRPα

以VEGF(R)为靶点药物的研发进展/Development progress of VEGF(R) target drugs

靶点ROR1会是下一个PD-1?/Will the target ROR1 be the next PD-1?

靶向NK细胞治疗肿瘤的双特异性抗体药物开发/Development of bispecific antibody drugs targeting NK cells to treat tumors

Claudin 18.2下一代创新免疫疗法黑马/Claudin 18.2 The next generation of innovative immunotherapy dark horse

 

第三届细胞与基因治疗创新论坛:

 

细胞免疫治疗产业发展趋势与政策环境解读/Development Trends and Policies of Cellular Immunotherapy Industry

CART产品开发新靶点新思路/CART product development new targets and new ideas

CART免疫细胞治疗的工艺开发,验证和产业化/Process development, verification and industrialization of CART immune cell therapy

双靶点CAR-T细胞治疗癌症的研究进展和展望/Research progress and prospects of dual-target CAR-T cell therapy for cancer

治疗肝癌CAR-T细胞产品的设计和临床研究/Design and clinical research of CAR-T cell products for the treatment of liver cancer

小组讨论: CAR-T细胞治疗火热的当下面临的潜在问题,未来破局之道 The potential problems faced by CAR-T cell therapy at the moment, and the future outlook

广谱多功能CAR-NK 细胞药物的研发/Development of Multifunctional Integrated CAR-NK Cell Drug

基因治疗药物研发与分析/Gene therapy drug development and analysis

溶瘤病毒产品的研发进展/Research and development progress of oncolytic virus products

下一代腺病毒载体+ 新技术助基因治疗腾飞/Next-generation Adenovirus Vector + New Technology Helps Gene Therapy Take Off

基因编辑技术及其应用/Gene editing technology and its application

从小众到大众→通用CAR-T未来已来/From niche to mass → General CAR-T's future is here

肿瘤微环境下的下一代细胞治疗产品开发/Development of next-generation cell therapy products in the tumor microenvironment

病毒载体开发和工艺优化/Viral vector development and process optimization

溶瘤病毒联合PD1/PD-L1治疗癌症/Oncolytic virus combined with PD1/PD-L1 to treat cancer

AAV在眼科疾病领域中的应用突破/Breakthrough in the application of AAV in the field of ophthalmic diseases

溶瘤病毒产品商业化生产的机遇和挑战/Opportunities and challenges for commercial production of oncolytic virus products

 

第二届CDMO未来发展论坛主要话题:

 

抗体药物生产上游工艺开发及优化/Upstream process development and optimization of antibody drug production

抗体药物生产下游连续工艺:当下趋势与挑战/Progression of continuous downstream processing of monoclonal antibodies: current trends and challenges

CDMO角度分析细胞与基因治疗产业化面临的挑战和未来展望/CDMO analysis of the challenges and future prospects of the industrialization of cell and gene therapy

抗体药物商业化生产的关键要素/The key elements of the commercial production of antibody drugs

基因治疗药物的生产工艺开发策略和案例分享/Gene therapy drug production process development strategy and case sharing

圆桌讨论:中国CDMO未来发展之路/Panel Discussion:The future development of China's CDMO

全球一次性工艺技术市场与展望/Global Single-use Bioprocessing Market Outlook and Forecast

一次性工艺技术在生物制药领域的应用机会与实践/Application opportunities and practices of disposable process technology in the field of biopharmaceuticals

生物制药:一次性生产工艺VS不锈钢生物反应器/Single-Use VS StainlessSteel Bioreactors for Biopharma

双抗CMC下游纯化及分析方法开发案例分享/Case sharing of double antibody CMC downstream purification and analysis method development

GmP生产中生产工艺变更和管理/Production process change and management in GmP production

药品全生命周期工艺开发和技术转移中的质量保证/Quality Assurance in Process Development and Technology Transfer of Drugs in Whole Life Cycle

全生命周期管理助力生物制药创新/Driving Innovation of BioPharma Products Through Life Cycle Planning

数字化技术助力生物药GMP生产/Pharma 4.0: Why digitize production

创新+国际化,打造全球领先的质量管理体系/Innovation + internationalization, to build a world-leading quality management system

基于QbD的细胞培养工艺开发

CDMO赋能中国生物制药发展/CDMO empowers China's biopharmaceutical development

 

临床前与临床开发论坛:

 

抗体偶联药物药代动力学研究进展/Research progress on the PK of antibody-conjugated drugs

生物药的免疫原性评价/Evaluation of immunogenicity of biological drugs

生物药的GLP安全性评价/GLP safety evaluation of biological drugs

临床前与临床试验数据的过程管理/Process management of pre-clinical and clinical trial data

小组讨论: 如何规范生物药的临床前研究,加快IND申报进程/Panel discussion: How to standardize the preclinical research of biological drugs and speed up the IND application process

创新药临床实验设计的考量/Considerations for the design of clinical trials of innovative drugs

人源化小鼠模型在肿瘤免疫新药研发中的应用/Application of humanized mouse model in the development of new tumor immune drugs

生物药国际多中心临床试验的成功要素/Successful factors for international multi-center clinical trials of biological drugs

ADC药物CMC工艺开发及临床研究策略/ADC drug CMC process development and clinical research strategy

生物制药IND到上市全生命周期CMC的重要性/The importance of CMC from biopharmaceutical IND to listing

创新生物药PK-PD研究中生物分析的考虑/Considerations of biological analysis in the research of innovative biological drugs PK-PD

数字化在临床使用中的应用/Application of digitization in clinical use

IND阶段CMC的评审要点/CMC review points in the IND phase

圆桌讨论: 中国临床前CRO行业发展现状及未来方向/Panel Discussion: Development Status and Future Direction of China's Preclinical CRO

免疫细胞治疗产品药学研究/CMC Research of Immune Cell Therapy Products

创新生物药临床研发中药学的挑战和应对/Challenges and countermeasures of CMC in clinical research and development of innovative biopharma

药物安全和药物警戒

 

小分子与创新药论坛:

 

小分子创新药物研发趋势和战略/Trends and Strategies of Small Molecule Innovative Drug Development

免疫代谢小分子药物的未来创新研发之路/The future innovative R&D road of immunometabolic small molecule drugs

小分子药物和肿瘤免疫联合治疗:未来突破方向/Combination therapy of small molecule drugs and tumor immunity: a breakthrough direction in the future

小分子药物开发热门靶点及全球研发现状/Popular targets for small molecule drug development and global R&D status

Kras靶向抗癌药物开发走向何方?/Where is Kras's targeted anti-cancer drug development going?

NASH新药研发:离成功还有多远/NASH new drug development: how far is it from success

AI赋能小分子多肽药物研发/AI empowers R&D of small molecule peptide drugs

一次性工艺技术在生物制药领域的应用机会与实践/Application opportunities and practices of disposable process technology in the field of biopharmaceuticals

新一代小分子药物晶体结构的解析技术——MicroED/A new generation of small molecule drug crystal structure analysis technology——MicroED

5 抗肿瘤新药SHP2抑制剂的开发/The discovery and development of First in Class SHP2 inhibitors

制剂创新和产品改良:布局、实践和展望/Formulation innovation and product improvement: layout, practice and outlook

创新药物制剂开发策略/Antibody drug formulation development strategy

靶向RNA小分子药物开发的进展和未来展望/Progress and future prospects of targeted RNA small molecule drug development

Protac技术助力新药研发/Protac technology helps new drug development

505 (b)(2)口服产品开发中常用的给药技术/505 (b)(2) Commonly used drug delivery techniques in the development of oral products

抗肿瘤多肽类药物研发进展和趋势/Progress and trends in the development of anti-tumor peptide drugs

多肽偶联药物(PDC) ——继ADC之后,新一代肿瘤靶向药物已然来临/Polypeptide-conjugated drugs (PDC)-after ADC, a new generation of tumor-targeted drugs has arrived

重组蛋白类药物的研发现状与趋势/Current status and trend of research and development of recombinant protein drugs



60个展位火热预订,演讲赞助,椅背赞助,横幅赞助等火热开选,9月1日前更有75折优惠等你抢!


往届会后报告,往届参会人员名单,展台,赞助方案等请联系工作人员

往届实录

Biofuture 2022 第三届生物医药未来领袖峰会Biofuture 2022 第三届生物医药未来领袖峰会

Biofuture 2022 第三届生物医药未来领袖峰会Biofuture 2022 第三届生物医药未来领袖峰会

Biofuture 2022 第三届生物医药未来领袖峰会


查看更多

会议日程


即将更新,敬请期待

会议嘉宾


即将更新,敬请期待

参会指南

会议门票


参会形式:

免费参观票:朋友圈转发会议信息附上推荐性评论

早鸟票(2021年9月1日前):1500/人(包含午餐和会议资料)

普通票:2500/人(包含午餐和会议资料)

查看更多

温馨提示
酒店与住宿: 为防止极端情况下活动延期或取消,建议“异地客户”与活动家客服确认参会信息后,再安排出行与住宿。
退款规则: 活动各项资源需提前采购,购票后不支持退款,可以换人参加。

标签: 药品

还有若干场即将举行的 药品大会

猜你喜欢

会议地点

部分参会单位

主办方没有公开参会单位
活动家_小程序快捷下单

微信扫一扫
分享给朋友

邮件提醒通知

分享到微信 ×

打开微信,点击底部的“发现”,
使用“扫一扫”即可将网页分享至朋友圈。

录入信息

请录入信息,方便生成邀请函